Select a Region North America


Dianna Cohen



Consulting (Strategy Management & Regulatory), Consulting (Strategy Management and HTA requirements), Launch Readiness, Market Access, Patient Journey

Dianna Cohen is a Principal at EVERSANA™ MANAGEMENT CONSULTING, with more than 17 years of life sciences experience in marketing, consulting, and strategy. She specializes in helping life science clients across different areas of commercialization, including launch, brand strategy, market access, and customer engagement models.

Prior to EVERSANA, Dianna was an Associate Principal at IQVIA. There, she was a part of the Launch, Brand and Commercial Strategy practice where she helped both large pharma and emerging biotech clients by providing customized and actionable strategy solutions for their business questions. Her therapeutic areas of expertise include various oncology indications, infectious diseases, CNS disorders, dermatology, and rare diseases.

In addition to consulting, Dianna has also held various marketing roles, including Product Manager and Global Marketing Manager at Avantor Performance Materials  (Covidien) for its Biopharma business division.

Dianna received her MBA from Lehigh University. She also holds a BS in Biochemical Engineering from Lehigh University’s P.C. Rossin College of Engineering and Applied Science.

Articles by Dianna Cohen

Critical Success Factors for Launching Products with Orphan Drug Designation

The Orphan Drug Act (ODA) was passed in 1983 to financially incentivize pharmaceutical companies to develop drugs for rare diseases or conditions, defined as a disease or condition that affects less than 200,000 people in the US.1 The financial incentives offered by the ODA are substantial and include tax credits up to 50% of the qualified clinical testing expenses for the taxable year, waived Prescription Drug User Fee Act (PDUFA) user fees that may be upwards of $3 million in 2022, and an extended market exclusivity period of seven years after approval.2 A recent analysis found that receiving an orphan drug designation does, on average, positively impact companies’ value as […]

Interested in scheduling a meeting or speaking event?


  • このフィールドは入力チェック用です。変更しないでください。